Supplements are quite popular in today’s world. More and more people are turning to health trends, eating natural foods, and exercising on a more frequent basis. Even though the human race boasts a longer life expectancy than ever before, people are still looking for opportunities to stay healthy for longer.
Elysium Health is the consumer health company behind the supplement Basis. Basis is clinically proven to increase levels of NAD+, an essential coenzyme in our cells. As we age, levels of NAD+ decrease. Basis works to increase those levels in humans.
The People Behind Elysium Health
Elysium Health was formed by two businessmen and a scientist in 2014. The company brought Basis—its first and to date only product—to market in 2015.
Dr. Leonard Guarente is the scientist within the trio. He has been a member of the faculty of the Massachusetts Institute of Technology since 1982. Throughout his 35-year tenure, he has spent the entirety of his career as the director of the Glenn Laboratory for Biology of Aging.
The two businessmen are Eric Marcotulli and Dan Alminana. Marcotulli worked in venture capital while Alminana worked in investment banking before joining Elysium Health.
Clinical Trials Proving the Effects of Basis
Unfortunately for consumers, most supplement manufacturers do not run their products through clinical trials. However, Elysium Health put Basis through a clinical trial in 2016.
The trials involved splitting 120 participants, ages 60 through 80, into three equal groups. Over the course of eight weeks, The first group received two capsules of Basis per day—the recommended daily dose, the second group received four capsules per day—twice the daily recommended dose, and the third group received a placebo.
The results, published in November 2017 in the academic journal npj: Aging and Mechanisms of Disease, demonstrated that within four weeks, the group The group receiving two capsules of Basis daily experienced an average increase of 40% in NAD+ levels. The group receiving four capsules daily experienced an average increase of 90% in NAD+ levels. In both cases, the increases were sustained throughout the duration of the trial. The placebo group did not experience an increase in NAD+ levels.